- Results are expected from the Phase II MITI IV trial in mid 2008.
This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.
It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.
- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.
Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.
- Top line results of the interaction studies to be announced by mid-2008.
TB-402 is being developed as an anti-coagulant for the prevention of
deep vein thrombosis (DVT) after orthopaedic surgery and prevention of
venous emboli in patients with atrial fibrillation. It is a novel human
antibody that partially blocks Factor VIII, an essential blood clotting
factor. The implicat
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved